Provectus Pharmaceuticals Inc.' PV-10 Phase 2 Final Data to be Presented at 2nd European PostASCO Melanoma Meeting 2012 on June 22, 2012

Published: May 09, 2012

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that Phase 2 final data on PV-10 for metastatic melanoma will be presented at the 2nd European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

Back to news